Abstract: An isolated immune regulatory cell having an exogenous cell death-inducing moiety attached to a surface thereof is disclosed herein. Additionally, a molecule comprising a cell death-inducing moiety heterologously attached to an immune regulatory cell-specific binding moiety is disclosed herein. Methods of generating and using same as well as pharmaceutical compositions comprising same are also disclosed.
Abstract: Isolated monoclonal antibodies which bind to human DEC-205 and related antibody-based compositions and molecules are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, as well as therapeutic and diagnostic methods for using the antibodies.
Type:
Grant
Filed:
December 17, 2012
Date of Patent:
April 18, 2017
Assignee:
Celldex Therapeutics Inc.
Inventors:
Tibor Keler, Lizhen He, Venky Ramakrishna, Laura A. Vitale
Abstract: The invention relates to dendritic cells produced from human induced pluripotent stems cells (iPSC). The invention also relates to methods for making and methods of using the dendritic cells of the invention.
Abstract: The present invention discloses a use of dendritic killer cell population for manufacturing medication. The dendritic killer cell population is generated by culturing peripheral blood mononuclear cells with effective amounts of various cytokines for an appropriate time period, and the conserved cytokine is IL-15. Meanwhile a pharmaceutical composition comprises the above dendritic killer cell population for treating cancers is also disclosed in the present invention.
Abstract: The present invention provides a formulation and method for preparing specific T cells, and a method for fabricating the formulation is also disclosed. The formulation can induce specific T cell responses, and comprises at least a cell population of dendritic killer cells presenting specific antigens. In addition, the method mentioned above for preparing specific T cells comprises following steps. A T cell population is provided, and then a formulation of preparing specific T cells is mixing with the T cell population. After cultivating, the specific T cells are harvested. Furthermore, the method for fabricating the above formulation comprises the following steps. First, a cell population of dendritic killer cells is provided. A target sample is then provided, and a step of making the cell population of the dendritic killer cells is co-cultivated with the target sample. After co-cultivating, a cell population of dendritic killer cells presenting specific antigens is harvested.
Abstract: The invention generally features compositions and methods for modulating an immune response. In particular embodiments, such compositions and methods modulate regulatory T cell suppressive activity.
Type:
Grant
Filed:
May 20, 2014
Date of Patent:
December 20, 2016
Assignee:
The Johns Hopkins University
Inventors:
Charles G. Drake, Drew M. Pardoll, Jonathan D. Powell, Derese Getnet, Edward L. Hipkiss, Joseph F. Grosso
Abstract: The invention relates to a method for in vitro maturation of at least one immate dendritic cell, comprising stimulating said immature dendritic cell with TNF?, IL-1?, IFN?, a TLR7/8 agonist and prostaglandin E2(PG). Furthermore, the invention elates to a composition comprising these factors as well as to mature dendritic cells produced by a method of the invention.
Type:
Grant
Filed:
February 6, 2014
Date of Patent:
December 6, 2016
Assignee:
Helmholtz Zentrum Munchen Deutsches Forschungszentrum fur Gesundheit und Umwelt (GmbH)
Inventors:
Dolores J. Schendel, Anke Zobywalski, Iris Bigalke
Abstract: The present invention provides T cell receptors (TCRs) having the property of binding to SLLMWITQC-HLA-A*0201, the SLLMWITQC SEQ ID NO:126 peptide being derived from the NY-ESO-1 protein which is expressed by a range of tumor cells. The TCRs have a KD for the said peptide-HLA complex of less than or equal to 1 ?M and/or have an off-rate (koff) of 1×10?3 S?1 or slower.
Type:
Grant
Filed:
December 14, 2015
Date of Patent:
December 6, 2016
Assignee:
ADAPTIMMUNE LIMITED
Inventors:
Jonathan Michael Boulter, Bent Karsten Jakobsen, Yi Li, Peter Eamon Molloy, Steven Mark Dunn
Abstract: The present invention is directed to antigen binding constructs comprising one or two epitope binding domains separated by a single chain Fc region of an antibody, wherein each epitope binding domain in capable of binding to VEGF, to dimers comprising two antigen binding constructs of the invention, pharmaceutical compositions comprising said dimers and their use in the treatment of diseases associated with VEGF signalling, such as diabetic macular edema (DME), wet age-related macular degeneration (Wet AMD), diabetic retinopathy, retinal vein occlusion (RVO), and corneal neovascularization, and polynucleotide sequences encoding said antigen binding constructs.
Type:
Grant
Filed:
July 25, 2012
Date of Patent:
November 22, 2016
Assignee:
Glaxo Group Limited
Inventors:
Claire Ashman, Ian Richard Catchpole, Zoe Hughes-Thomas, Alan Peter Lewis, Michael Steward
Abstract: This invention relates to cellular-based therapies for increasing the level of regulatory T cells (Treg) and/or decreasing the level of pro-inflammatory T cells (Th17) to induce anergy or immune tolerance. To provide these therapeutic effects, two allogeneic leukocyte populations are contacted (in vivo, in vitro or ex vivo) and one of these leukocyte population is modified to bear on its surface a low-immunogenic biocompatible polymer so as to prevent pro-inflammatory allo-recognition. Cellular-based preparations and processes for achieving cellular therapy are also provided.
Type:
Grant
Filed:
July 12, 2013
Date of Patent:
November 22, 2016
Assignee:
CANADIAN BLOOD CERVICES
Inventors:
Mark D. Scott, Duncheng Wang, Wendy M. Toyofuku
Abstract: The present invention relates to compositions and methods of using those compositions for the diagnosis and treatment of immune related diseases.
Type:
Grant
Filed:
October 9, 2012
Date of Patent:
November 22, 2016
Assignee:
Genentech, Inc.
Inventors:
Hilary Clark, Dan Eaton, Lino Gonzalez, Jane Grogan, Jason Hackney, Kristin Bowles, Xin Yu
Abstract: The invention relates to a composition which contains at least one anti-slan antibody and to its diagnostic and therapeutic use. The composition according to the invention comprises: a) at least one anti-slan antibody, b) at least one binding unit which binds to a co-stimulus binding to a co-stimulus-specific receptor on dendritic cells, thereby bringing about the modulation, preferably the activation, of said dendritic cells, and c) at least one antigen. The invention furthermore comprises anti-slan antibodies which include CDRs with the following sequences: variable region of the heavy chain: CDR1 (SEQ ID No. 1), CDR2 (SEQ ID No. 2), where Xaa is selected from among M, L, F, or I, preferably from among M or I, CDR3 (SEQ ID No. 5) and variable region of the light chain: CDR1 (SEQ ID No. 6), where Xaa is selected from among S, T, N, Q, H, K or R, preferably from among S or N, CDR2 (SEQ ID No. 9) and CDR3 (SEQ ID No. 10).
Abstract: Methods for inducing, expanding, and/or generating alloantigen-specific regulatory T cells. Alloantigen-specific regulatory T cells can be induced, expanded, and/or generated from naive CD4+CD25? T cells by using CD40-activated B cells. The regulatory T cells can be human T cells. In one embodiment, the alloantigen-specific human regulatory T cells can be CD4highCD25+Foxp3+ regulatory T cells.
Type:
Grant
Filed:
January 10, 2014
Date of Patent:
November 1, 2016
Assignees:
VERSITECH LIMITED, THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Inventors:
Wenwei Tu, Yu-Lung Lau, David Bram Lewis
Abstract: The present invention provides methods for producing cell populations enriched for stable, regulatory T cells (Tregs). In particular, the invention relates to methods for culturing T cells such that the final culture is enriched for stable, regulatory T cells. It also relates to methods for stabilizing regulatory T cells. Also provided are compositions enriched for stable, regulatory T cells, which are useful for treating individuals in need of such treatment. The methods and compositions disclosed herein can also be used to treat an individual suffering from an immune-mediated disease.
Type:
Grant
Filed:
December 17, 2012
Date of Patent:
November 1, 2016
Assignee:
The United States of America, as represented by the Secretary, Department of Health and Human Services
Abstract: Disclosed herein are new methods of producing a novel line of dendritic cells. The method comprises subjecting a sample of hematopoietic stem/precursor cells to a first feeder culture system that is supplemented with a first set of factors and a second feeder culture system supplemented with a second group of factors. The disclosure also pertains to new cell types that may be used as cancer immunotherapy.
Abstract: The present invention includes compositions and methods for making and using anti DC-ASGPR antibodies that can, e.g., activate DCs and other cells.
Abstract: The present invention relates to methods of treating proliferative disorders, particularly immunoproliferative and autoimmune disorders, and methods of producing antibodies which bind NK cell receptors for use in therapeutic strategies for treating such disorders, particularly to deplete cells involved in the immunoproliferative pathology.
Type:
Grant
Filed:
October 13, 2006
Date of Patent:
September 20, 2016
Assignees:
INNATE PHARMA, S.A., UNIVERSITY OF GENOVA, NOVO NORDISK A/S
Inventors:
Francois Romagne, Alessandro Moretta, Mathieu Blery, Petrus Johannes Louis Spee, Ulrik Morch
Abstract: Methods are provided for inhibiting or enhancing down-regulation of an antigen-activated HLA-E+ T cell by an HLA-E-restricted CD8+ T cell comprising contacting the HLA-E+ T cell and CD8+ T cell with an agent which inhibits or enhances, respectively, binding between (i) T cell receptor (TCR) on the surface of the CD8+ T cell and (ii) a self peptide presented by HLA-E on the surface of the HLA-E+ T cell, thereby inhibiting or enhancing, respectively, down-regulation of the antigen-activated HLA-E+ T cell. Compositions comprising agents which inhibit or enhance/activate, respectively, binding between (i) T cell receptor (TCR) on the surface of a CD8+ T cell and (ii) a self peptide presented by HLA-E on the surface of a HLA-E+ T cell, and assays for identifying such agents, are provided.
Type:
Grant
Filed:
February 7, 2013
Date of Patent:
August 23, 2016
Assignee:
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
Abstract: This invention relates to an immunosuppressive cell, and methods of obtaining the cell and using the cell. The immunosuppressive cell is obtained by culturing a precursor cell in a medium that contains a GRO chemokine.
Abstract: We provide new methods of in vitro or in vivo enhancing the T-cell stimulatory capacity of human DCs and the use thereof in cancer vaccination. The method includes the introduction of different molecular adjuvants to human DCs by contacting or modifying them with mRNA or DNA molecule(s) encoding CD40L, and CD70 or constitutively active TLR4 (caTLR4).
Type:
Grant
Filed:
August 23, 2013
Date of Patent:
August 9, 2016
Assignee:
Vrije Universiteit Brussel
Inventors:
Kris Maria Magdalena Thielemans, Aude Bonehill